Michael Hallek - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Michael Hallek's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Michael Hallek
Verified
Editorial Board, Blood Cancer Journal
Cologne
Beats
Representation In Film , Mental Health, Anti Racism , Body Positivity, Parenthood, Feminism , Asian American Identity
foreign policy, art, music, hobbies, etc.
Content
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody - Nature Medicine
By Maximilian Merz, David Fandrei, Eva Heger, Viola Schweinsberg, Uwe Platzbecker, Michael Hallek, Kristin Reiche, Florian Große, Nhu-Nguyen Pham| Nature Verified AbstractChimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. Nine months after CAR T therapy, he developed a symptomatic leukemic peripheral T cell lymphoma with cutaneous and intestinal involvement.
By Michael Hallek| Wiley Online Library Verified 1 Introduction and Disease Overview In the most recent update of the SEER database, the age-adjusted incidence of chronic lymphocytic leukemia (CLL) was 4.6 per 100 000 inhabitants per year [1], which makes CLL the most common type of leukemia. The median age at diagnosis is 70 years [1]. Less than 10% of patients with CLL are younger than 45 years. More male than female patients (1.9:1) are affected, and this gender effect seems to be stable across all ethnicities.
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody - Nature Medicine
By Maximilian Merz, David Fandrei, Eva Heger, Viola Schweinsberg, Uwe Platzbecker, Michael Hallek, Kristin Reiche, Florian Große, Nhu-Nguyen Pham| Nature Verified AbstractChimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. Nine months after CAR T therapy, he developed a symptomatic leukemic peripheral T cell lymphoma with cutaneous and intestinal involvement.
Company Info
Blood Cancer Journal
Hoboken, New Jersey, United States
'+1 201-748-6000